Table 3.
Effectiveness and cost-effectiveness of AP-MRI screening.
| Screening strategies | BC deaths | Screen-detected cancers | Radiation-induced tumour | Interval cancers | Discounted LYGa | Discounted ACERa (k€/LYG) | ICER (k€/LYG) |
|---|---|---|---|---|---|---|---|
| MAM 50-74 | 736 (3) | 573 (2) | 18 (0.4) | 671 (2) | – | – | – |
| Base scenarios | |||||||
| Biennial screening | |||||||
| Strategy A | 719 (3) | 635 (2) | 15 (0.4) | 609 (3) | 132 (2) | 16.0 (0.2) | 18.2 |
| Strategy B | 715 (3) | 657 (2) | 14 (0.4) | 589 (2) | 145 (1) | 17.8 (0.2) | ED |
| Strategy C | 713 (3) | 674 (2) | 13 (0.4) | 585 (3) | 149 (1) | 18.8 (0.1) | ED |
| Strategy D | 671 (2) | 805 (2) | 4 (0.2) | 441 (2) | 501 (5) | 21.7 (0.2) | 24.7 |
| Strategy E | 655 (2) | 891 (2) | 2 (0.1) | 362 (1) | 554 (4) | 23.9 (0.2) | ED |
| Strategy F | 649 (2) | 952 (2) | NA | 347 (2) | 562 (5) | 25.7 (0.2) | 58.7 |
| Alternative scenarios | |||||||
| Triennial screening | |||||||
| Strategy A-3 | 724 (3) | 614 (2) | 15 (0.4) | 630 (2) | 91 (1) | 15.1 (0.2) | 15.5 |
| Strategy B-3 | 723 (3) | 620 (2) | 14 (0.4) | 625 (2) | 95 (1) | 15.5 (0.2) | ED |
| Strategy C-3 | 721 (3) | 634 (1) | 14 (0.4) | 622 (2) | 98 (1) | 17.0 (0.3) | ED |
| Strategy D-3 | 694 (2) | 697 (1) | 3 (0.2) | 507 (2) | 334 (7) | 20.3 (0.4) | 23.0 |
| Strategy E-3 | 690 (2) | 740 (2) | 2 (0.1) | 506 (2) | 353 (4) | 21.4 (0.3) | ED |
| Strategy F-3 | 684 (2) | 790 (2) | NA | 500 (2) | 362 (5) | 23.6 (0.3) | ED |
| Quadrennial screening | |||||||
| Strategy A-4 | 731 (3) | 586 (2) | 15 (0.4) | 657 (3) | 52 (1) | 14.7 (0.2) | 14.7 |
| Strategy B-4 | 729 (3) | 596 (2) | 14 (0.4) | 649 (2) | 59 (1) | 17.3 (0.3) | ED |
| Strategy C-4 | 728 (3) | 602 (2) | 14 (0.4) | 652 (3) | 60 (1) | 18.2 (0.3) | ED |
| Strategy D-4 | 727 (2) | 567 (2) | 3 (0.2) | 672 (2) | 158 (5) | 23.4 (0.7) | ED |
| Strategy E-4 | 713 (2) | 640 (2) | 2 (0.1) | 605 (2) | 204 (5) | 25.9 (0.6) | ED |
| Strategy F-4 | 711 (2) | 660 (2) | NA | 622 (2) | 205 (5) | 27.5 (0.7) | ED |
Abbreviations: BC = Breast cancer; LYG = Life year gained; ACER = Average cost-effectiveness ratio; ICER = Incremental cost-effectiveness ratio; ED = Extended dominance.
a
A discounting rate of 3% was applied for both costs and LYG. All data expressed as mean (SEs) per 10,000 women screened.